Latest From Pfenex Inc.
The head of the UK’s health technology assessment body NICE is stepping down, while the country’s medicines agency, the MHRA, will have an interim chief in the run-up to the UK’s planned Brexit from the European Union on 31 October.
Firms that achieved recognition at last year’s Global Generics & Biosimilars Awards have continued to build on that success in the months since.
The EMA has formally accepted for filing Alvogen and Pfenex’ centralized marketing authorization application for a biosimilar rival to Lilly’s Forsteo teriparatide blockbuster.
- Drug Discovery Tools
- Large Molecule
- Synthesis Technologies, Production Processes
- Generic Drugs
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Pfenex Inc.
- Senior Management
Evert (Eef) Schimmelpennink, Pres. & CEO
Susan Knudson, CFO
Patrick K Lucy, CBO
Hubert C Chen, MD, CMO & CSO
- Contact Info
Phone: (858) 352-4400
10790 Roselle St.
San Diego, CA 92121
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.